The Fort Worth Press - Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes

USD -
AED 3.672505
AFN 64.502368
ALL 81.998222
AMD 357.803769
ANG 1.790403
AOA 918.000351
ARS 1559.243988
AUD 1.491024
AWG 1.8025
AZN 1.697591
BAM 1.782854
BBD 2.012735
BDT 124.411466
BGN 1.77347
BHD 0.377107
BIF 3003.463993
BMD 1
BND 1.288879
BOB 11.707704
BRL 5.899
BSD 0.999385
BTN 93.383593
BWP 14.117915
BYN 2.997958
BYR 19600
BZD 2.009818
CAD 1.431095
CDF 2285.00014
CHF 0.842915
CLF 0.025574
CLP 1006.490009
CNY 6.667797
CNH 6.668405
COP 3354.71
CRC 444.296568
CUC 1
CUP 23.984575
CVE 100.51779
CZK 22.22175
DJF 177.949763
DKK 6.802565
DOP 60.418499
DZD 137.053072
EGP 53.820098
ERN 15
ETB 164.020438
EUR 0.91005
FJD 2.28525
FKP 0.76038
GBP 0.760375
GEL 2.590602
GGP 0.76038
GHS 11.732317
GIP 0.76038
GMD 73.499493
GNF 8859.697901
GTQ 7.637401
GYD 209.002981
HKD 7.844715
HNL 26.862474
HRK 6.831965
HTG 131.020966
HUF 335.920292
IDR 18253
ILS 3.282095
IMP 0.76038
INR 93.28535
IQD 1514.984389
IRR 1933164.496166
ISK 124.679944
JEP 0.76038
JMD 158.502846
JOD 0.709056
JPY 159.949498
KES 130.060512
KGS 87.449537
KHR 4071.103008
KMF 448.999585
KPW 900.00035
KRW 1328.189719
KWD 0.31162
KYD 0.832836
KZT 444.440393
LAK 22515.053033
LBP 89590.84067
LKR 332.58429
LRD 167.887437
LSL 17.179374
LTL 2.95274
LVL 0.60489
LYD 6.463111
MAD 9.953508
MDL 18.347645
MGA 4544.315048
MKD 55.964687
MMK 2099.801407
MNT 3600.814049
MOP 8.076574
MRU 40.612196
MUR 46.840266
MVR 15.416238
MWK 1732.793079
MXN 18.845105
MYR 4.113204
MZN 63.915562
NAD 17.179061
NGN 1351.659682
NIO 36.77352
NOK 9.693335
NPR 149.412703
NZD 1.80985
OMR 0.384501
PAB 0.999385
PEN 3.411744
PGK 4.495877
PHP 63.690193
PKR 276.292258
PLN 4.01981
PYG 6255.270079
QAR 3.643308
RON 4.864696
RSD 107.053982
RUB 81.823857
RWF 1478.922348
SAR 3.751382
SBD 8.137041
SCR 13.883305
SDG 601.50065
SEK 10.14478
SGD 1.289585
SHP 0.757117
SLE 22.795018
SLL 20969.503664
SOS 571.095199
SRD 37.384497
STD 20697.981008
STN 22.333535
SVC 8.744046
SYP 13002.000337
SZL 17.176326
THB 33.896501
TJS 9.188906
TMT 3.5
TND 3.026701
TOP 2.40776
TRY 50.46722
TTD 6.7815
TWD 32.936502
TZS 2655.017981
UAH 45.116247
UGX 4186.987794
UYU 40.602566
UZS 12002.151381
VES 916.62795
VND 25755
VUV 120.949122
WST 2.823281
XAF 596.953744
XAG 0.022206
XAU 0.000268806004
XCD 2.70255
XCG 1.801044
XDR 0.707052
XOF 596.953744
XPF 108.71765
YER 236.550276
ZAR 17.251035
ZMK 9001.198647
ZMW 20.525699
ZWL 321.999592
SSP 5879.599296
MXV 2.113026
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes

Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes

Inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® follows the Company's August 2026 initial public offering and takes effect with FTSE Russell's December 2026 reconstitution

Text size:

RALEIGH, NC / ACCESS Newswire / November 19, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it is set to join the broad-market Russell 2000®, Russell 3000® Index, and Russell Microcap® Index as part of FTSE Russell's December 2026 semi-annual reconstitution of the Russell US Indexes. Membership will take effect after the U.S. equity markets close on Friday, December 11, 2026, according to the preliminary list of additions FTSE Russell published on November 13, 2026.

Russell index membership is determined by objective, rules-based criteria, chiefly total market capitalization as of the rank day. The December 2026 reconstitution is the first December reconstitution of the Russell US Indexes in more than three decades, following FTSE Russell's move to a semi-annual (June and December) schedule this year.

"Joining the Russell indexes just four months after our IPO is an important milestone for Vogenx," said James Green, Chief Executive Officer of Vogenx. "Index inclusion broadens our visibility with institutional and index-based investors at a time when we are advancing mizagliflozin in our Phase 2b EMERGE study for post-bariatric hypoglycemia, a serious condition with no FDA-approved treatment. We look forward to engaging with a wider investor base as we work toward key clinical milestones."

About the Russell US Indexes

The Russell US Indexes, maintained by FTSE Russell, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. The Russell 3000® Index measures the performance of the broad U.S. equity market, and the Russell 2000® Index, a subset of the Russell 3000, is a leading benchmark for U.S. small-capitalization companies. Beginning in 2026, the Russell US Indexes are reconstituted twice a year, in June and December.

About Mizagliflozin

Mizagliflozin is an investigational, first-in-class, orally administered, minimally absorbed small-molecule inhibitor of the sodium-dependent glucose transporter 1 (SGLT1). Designed to act locally in the small intestine, mizagliflozin reduces and delays intestinal glucose absorption, lowering postprandial glucose absorption. It has been studied in more than 500 subjects across 10 clinical studies. Vogenx holds an exclusive license to mizagliflozin from Kissei Pharmaceutical Co., Ltd. covering all territories outside Japan, Korea and Taiwan.

About Vogenx, Inc.

Vogenx, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism where there is significant unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected inclusion in the Russell 3000®, Russell 2000® and Russell Microcap® Indexes, the timing thereof, the anticipated benefits of index inclusion, and the Company's clinical development plans and milestones. Index membership remains subject to FTSE Russell's final determination. Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "will" and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this release, and Vogenx specifically disclaims any obligation to update them, except as required by law.

Contacts
Harrison Seidner, PhD and Nilesh Talele, PhD
WaterSeid Partners, Inc.
[email protected]

SOURCE: Vogenx, Inc.



View the original press release on ACCESS Newswire

M.T.Smith--TFWP